Physician

Mohammad A Quasem, MD

According to 2025 Medicare claims, Mohammad Quasem, MD (NPI: 1578559399) practices internal medicine in the Binghamton, NY market, with the plurality of this provider's patient population coming from Broome, NY. This provider's primary affiliated billing organization is UNITED HEALTH SERVICES HOSPITALS, INC. (NPI: 1962463851; TIN: 161165049) and primary practice location at 13850-2141. Quasem is affiliated with the Keystone ACO (ACO ID: A1552), participating under the MSSP model.

Quasem's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 588 traditional Medicare patients, billed 3,599 HCPCS/CPT codes, and received $201,652 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 2,143 prescription claims across 554 beneficiaries totaling $214,709 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 150 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $475,043 to $201,652. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $281,728 and ending at $214,709. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,163	5,599	$475,043
2016	1,122	5,933	$465,052
2017	1,074	8,492	$427,560
2018	1,003	7,021	$420,390
2019	952	5,904	$407,383
2020	821	13,397	$346,630
2021	783	14,561	$371,305
2022	722	4,158	$303,725
2023	620	4,539	$240,551
2024	588	3,599	$201,652

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	531	3,113	$281,728
2016	511	2,889	$188,005
2017	511	2,753	$153,905
2018	511	2,847	$157,096
2019	492	2,409	$288,674
2020	425	2,011	$268,239
2021	462	1,860	$238,931
2022	483	2,057	$217,786
2023	514	2,243	$315,561
2024	554	2,143	$214,709

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	104	$9,330
2016	N/R	73	$5,331
2017	N/R	84	$5,297
2018	N/R	249	$8,829
2019	N/R	261	$8,417
2020	N/R	154	$5,954
2021	N/R	149	$5,598
2022	N/R	151	$3,933
2023	N/R	173	$3,612
2024	N/R	150	$2,833

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	44	302	$276
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	57	99	$91
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	364	653	$71
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	123	335	$60
90935	Hemodialysis procedure with physician evaluation	45	134	$54

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	48	3,840	$69,109
Jardiance	Empagliflozin	28	2,520	$46,107
Calcitriol	Calcitriol	675	56,851	$12,199
Cinacalcet Hcl	Cinacalcet Hcl	29	1,860	$8,552
Hydralazine Hcl	Hydralazine Hcl	127	9,286	$2,301

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7520	Sirolimus, oral, 1 mg	N	N/R	20	$1,086
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	29	$527
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	45	$527
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	25	$472
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	31	$221

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Mohammad A. Quasem, MD?

Tedicare shows public-source Medicare data for Mohammad A. Quasem, MD (NPI 1578559399), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mohammad A. Quasem, MD have ACO affiliation data?

Mohammad A. Quasem, MD is shown with ACO affiliation data for Keystone ACO (MSSP, ACO ID A1552).

What billing organization is linked to Mohammad A. Quasem, MD?

Mohammad A. Quasem, MD is linked to UNITED HEALTH SERVICES HOSPITALS, INC. (billing NPI 1962463851) in the available physician profile data.

Does Mohammad A. Quasem, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.